Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04665752 · ClinicalTrials.gov registry record

Ocular Findings and Viral Persistence in Ocular Fluids in COVID-19 Survivors

A clinical trial, sponsored by National Eye Institute (NEI).

Terminated
Registry status
8
Enrollment target

NCT04665752 is a clinical trial that was terminated before completion, run by National Eye Institute (NEI). The registered enrollment target is 8 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04665752 was terminated before completion, sponsored by National Eye Institute (NEI).

TERMINATED
Registry status
8 participants
Enrollment target

Study Summary

Background: Some people who have had COVID-19 experience changes in the eye. Sometimes these changes are subtle and may not affect vision. Researchers want to learn how many people experience these eye changes and where in the eye they occur to better understand the outcomes of COVID-19 and its treatments. Objective: To examine possible changes in the eye that might have occurred as a result of COVID-19. Eligibility: Adults age 18 and older who were diagnosed with COVID-19 and recovered. Design: Participants will be screened with a medical history and physical exam. They will have blood tests. Participants will have an eye exam. Their pupils will be dilated with eye drops. Eye pressure and movements will be measured. Participants will have optical coherence tomography. Pictures will be taken of the retina and the inside of the eyes. Participants may have fluorescein angiography and indocyanine green angiography. They will be given a dye through an intravenous line. The dye will travel up to the blood vessels in their eyes. Pictures will be taken of the dye as it flows through the blood vessels. Participants may have electroretinography to test the retina. They will sit in the dark with their eyes patched for 30 minutes. Then they will watch flashing lights while wearing contact lenses that sense signals from the retina. Participants may have adaptive optics-assisted imaging. They will look at a specific location while images are taken of the retina. During the study, participants will have blood drawn through a needle in their arm. Fluid or tissue from the eye may be obtained if participants have a medically needed procedure. Participation will last for 12 months.

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2021-02-02
Est. Completion 2022-01-28

Sponsor

National Eye Institute (NEI)

221 total trials

What the Registry Record Tells You About NCT04665752

The ClinicalTrials.gov registry entry for NCT04665752 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Eye Institute (NEI), which has 221 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT04665752 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04665752 about?

NCT04665752 is a clinical study titled "Ocular Findings and Viral Persistence in Ocular Fluids in COVID-19 Survivors". Background: Some people who have had COVID-19 experience changes in the eye. Sometimes these changes are subtle and may not affect vision. Researchers want to learn how many people experience these eye changes and where in the eye they occur to better understand the outcomes of COVID-19 and its tre...

What is the current status of trial NCT04665752?

This trial is currently terminated. The enrollment target is 8 participants. The study started on 2021-02-02. Estimated completion is 2022-01-28.

Who is sponsoring clinical trial NCT04665752?

This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.